These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 6966932)

  • 1. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 2. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
    Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
    Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F; Van den Berghe G
    Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
    Smith CM; Henderson JF
    Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
    Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
    Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of ADA inhibition on B cell differentiation in the rat.
    Barton RW
    Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
    Ratech H; Thorbecke GJ; Hirschhorn R
    Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
    Shewach DS; Plunkett W
    Biochem Pharmacol; 1982 Jun; 31(11):2103-9. PubMed ID: 6180754
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypnotic effects of deoxycorformycin in rats.
    Radulovacki M; Virus RM; Djuricic-Nedelson M; Green RD
    Brain Res; 1983 Jul; 271(2):392-5. PubMed ID: 6604561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pentostatin (2'deoxycoformycin), an inhibitor of adenosine deaminase, on type II collagen-induced arthritis in rats.
    Gilbertsen RB
    J Immunopharmacol; 1985; 7(3):325-41. PubMed ID: 3877119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine and hypoxic vasodilatation.
    Dóra E
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
    Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition-state stabilization by adenosine deaminase: structural studies of its inhibitory complex with deoxycoformycin.
    Frick L; Wolfenden R; Smal E; Baker DC
    Biochemistry; 1986 Apr; 25(7):1616-21. PubMed ID: 3486673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
    Lum CT; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
    [No Abstract]   [Full Text] [Related]  

  • 20. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
    Kotb M; Veit BC
    Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.